tag:blogger.com,1999:blog-8992739065445039328.post8184068981207005395..comments2023-09-13T04:31:31.093-07:00Comments on California Healthcare Institute: Executive Spotlight: Kleanthis Xanthopoulos, Ph.D., CEO of Regulus Therapeutics Inc.Nicole Beckstrandhttp://www.blogger.com/profile/14428210901836891139noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-8992739065445039328.post-6022039843788831242012-05-03T14:45:05.322-07:002012-05-03T14:45:05.322-07:00Kleanthis,
Regulus is a fine company, and you'...Kleanthis,<br />Regulus is a fine company, and you're a friend of Atlas and me. But to say you've scares away the competition? Come on, thats crazy.<br />MiRagen is a great company that we started at the same time and has done very well. Santaris is in the microRNA field and is the only one of the group with a clinical stage - sorry, Post-PoC clinical stage program. They may have other issues, but its unfair to say they aren't players. Mirna, Groove are newer companies in the field, and I wish them well. So there are lots of us who aren't afraid of Regulus. In fact, I hope Regulus' programs do well and further validate the important value of microRNA based drugs. But let's stop the posturing that you dominate the field. You don't. It's an exciting, active field today with high hopes for the future.<br />Brucebbhttps://www.blogger.com/profile/00215470948577007184noreply@blogger.com